Chronic Obstructive Pulmonary Disease Drugs Pipeline Market Report 2022: Comprehensive Information on 70+ Companies and 70+ Drugs in Pipeline – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–Clinical trial “Chronic Obstructive Pulmonary Disease – Pipeline Insight, 2022” has been added to from ResearchAndMarkets.com offer.

The report provides comprehensive information on 70+ companies and 70+ drugs under development in the Chronic Obstructive Pulmonary Disease pipeline landscape. It covers pipeline drug profiles, including clinical and non-clinical stage products. It also covers therapeutic evaluation by product type, stage, route of administration and molecule type. It further highlights inactive pipeline products in this space.

A detailed picture of the Chronic Obstructive Pulmonary Disease pipeline landscape is provided, which includes the disease overview and Chronic Obstructive Pulmonary Disease treatment guidelines. The assessment part of the report includes an in-depth Chronic Obstructive Pulmonary Disease business assessment and clinical evaluation of the pipeline products under development.

In the report, a detailed description of the drug is given including the drug’s mechanism of action, clinical studies, NDA approvals (if any) and product development activities including technology, disease collaborations chronic obstructive pulmonary disease, licensing, mergers and acquisitions, financing, designations, and other product-related details.

Report Highlights

Companies and academics are working to assess challenges and seek out opportunities that can influence chronic obstructive pulmonary disease R&D. The therapies under development are focused on new approaches to treat/improve chronic obstructive pulmonary disease.

Chronic Obstructive Pulmonary Disease Emerging Drug Chapters

This segment of Chronic Obstructive Pulmonary Disease report contains its detailed analysis of various drugs at different stages of clinical development including Phase II, I, Preclinical and Discovery. It also helps to understand details of clinical trials, expressive pharmacological action, agreements and collaborations, as well as the latest news and press releases.

Chronic Obstructive Pulmonary Disease Emerging Drugs

Benralizumab: AstraZeneca

Benralizumab (FASENRA) is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near complete depletion of eosinophils by apoptosis (programmed cell death). The drug is US FDA approved for asthma and is currently in development for other respiratory and immunological disorders such as COPD, atopic dermatitis and others.

The drug was earlier in the GALATHEA and TERRANOVA trials (randomized, double-blind, placebo-controlled, parallel-group trials that evaluated the safety and efficacy of Fasenra 30mg and 100mg in preventing exacerbations of COPD ). Currently, the drug is in RESOLUTE (Phase III trial) to assess its efficacy and safety.

MV130: Inmunotek SL

MV130 (BACTEK) is a mucosal bacterial vaccine or polyvalent bacterial vaccine spray administered sublingually to treat recurrent respiratory tract infections in children and adults. MV130 plays a relevant role in modulating the functional activity of innate and adaptive immune response by stimulating dendritic cells, which are part of innate immunity. A phase III clinical trial is evaluating MV130 in patients with COPD. At present, the trial is ongoing in Spain.

SB-240563: GlaxoSmithKline

SB-240563 (mepolizumab) is a humanized monoclonal antibody that prevents human interleukin 5 (hIL-5) from binding to its receptor. Early clinical studies investigated the safety and efficacy of SB-240563 for the treatment of asthma and atopic dermatitis (AD). SB-240563 reduced peripheral and tissue eosinophils in asthmatic patients and healthy volunteers. Currently, it is in Phase III clinical trials.

SAR440340: Sanofi/Regeneron

SAR440340 (Itepekimab) is a humanized IgG4P monoclonal antibody that prevents human interleukin 33 (hIL-33) from binding to its receptor. IL-33 is an epithelial cytokine that initiates and amplifies type 2 and type 1 innate and adaptive inflammatory pathways in response to epithelial insults due to exposure to allergens, viruses, cigarette smoke and pollutants. SAR440340 was invented using Regeneron’s proprietary VelocImmune technology which produces optimized fully human antibodies and is jointly developed by Regeneron and Sanofi under a global collaboration agreement.

CHF 6001: Chiesi Farmaceutici SpA

CHF6001 is a novel inhaled phosphodiesterase-4 (PDE-4) inhibitor developed as an extra-thin formulation (i.e. with a mass median aerodynamic diameter ?2 ?m) and low systemic exposure. This allows CHF6001 to reach a therapeutic concentration in the target organ, the lung, with reduced systemic exposure, limiting systemic adverse effects. The drug is administered by a dry powder inhaler (DPI NEXthaler).

YPL 001: YungjinPharm. Co., Ltd.

YPL 001 is a drug molecule that belongs to the class of anti-inflammatory and antihistamine drugs. The drug is being developed for COPD. YPL-001 is a product developed using wild chives, which grow naturally in nature, as a raw material. A phase II trial was conducted in US hospitals to assess the drug’s safety in patients with moderate to severe COPD. In phase I studies, YPL-001 was well tolerated in healthy subjects after single (up to 320 mg) and multiple (up to 240 mg twice daily) administration. [BID]) oral doses without serious adverse events (AEs).

Main topics covered:

introduction

Summary

Chronic Obstructive Pulmonary Disease: Overview

  • causes

  • Action mechanism

  • Signs and symptoms

  • Diagnostic

  • Disease management

Pipeline therapeutics

Therapeutic assessment

  • Assessment by product type

  • Assessment by stage and type of product

  • Evaluation by route of administration

  • Assessment by stage and route of administration

  • Evaluation by type of molecule

  • Evaluation by stage and type of molecule

  • Chronic Obstructive Pulmonary Disease – The Editor’s Analytical View

In-depth business assessment

  • Chronic Obstructive Pulmonary Disease Business Collaborations, Licensing, Acquisition – Deal Value Trends

Collaborative agreements on chronic obstructive pulmonary disease

  • Analysis of company-company collaborations (licenses / partnerships)

  • Analysis of company-university collaborations (licenses / partnerships)

Late-stage products (Phase III)

Benralizumab: AstraZeneca

  • Product Description

  • Research and development

  • Product development activities

  • Drug profiles in the detailed report

Mid-term products (Phase II)

YPL 001: YungjinPharm. Co., Ltd.

  • Product Description

  • Research and development

  • Product development activities

  • Drug profiles in the detailed report

Early Stage Products (Phase I/II)

CHF6366: Chiesi Farmaceutici

  • Product Description

  • Research and development

  • Product development activities

  • Drug profiles in the detailed report

Inactive products

  • Comparative analysis

  • Chronic Obstructive Pulmonary Disease Key Companies

  • Chronic Obstructive Pulmonary Disease Key Products

  • Chronic Obstructive Pulmonary Disease – Unmet Needs

  • Chronic Obstructive Pulmonary Disease – Market Drivers and Barriers

  • Chronic obstructive pulmonary disease – future outlook and conclusion

  • Analysts’ Views on Chronic Obstructive Pulmonary Disease

  • Chronic Obstructive Pulmonary Disease Key Companies

appendix

Companies cited

  • GlaxoSmithKline

  • Sanofi

  • Chiesi Farmaceutici SpA

  • United Therapeutics Corporation

  • Verona Pharma plc

  • Astra Zeneca

  • Immunotek

  • Astrazeneca

  • Yungjin Pharmacy. Co., Ltd.

  • Pulmotect, Inc.

  • Pharmaceutical Tetherex

  • CSL Behring; Organic Grifols

  • Astra Zeneca

  • Novartis

  • Genentech

  • Vertex Pharmaceuticals

  • Glenmark Pharmaceuticals

  • Emera Med

  • Afimmunized

  • Mereo BioPharma

  • Synairgen

  • Adamis Pharmaceuticals

  • Quercegen Pharmaceuticals LLC

  • Regend Therapeutic

  • Idorsia Pharmaceuticals

  • Meridigen Biotech Co., Ltd.

  • Pulmator

  • Eisai

  • GlaxoSmithKline

  • Boehringer Ingelheim

  • EpiEndo Pharmaceuticals

  • 3SBio

  • OmniSpirant

  • Rhizen Pharmaceuticals

  • Predict pharmaceuticals

  • Brickell Biotech

For more information on this clinical trial report, visit https://www.researchandmarkets.com/r/uayxey

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

Comments are closed.